Mirtamor (Mirtazapine)

Mirtazapine, the active ingredient in Mirtamor, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep, and appetite.

GNH USA supplies Mirtamor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution. Our network ensures timely delivery and regulatory compliance across multiple regions.

Mirtazapine is indicated for depressive disorders and works by modulating noradrenergic and serotonergic pathways.

- Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depression in adults: enhances sleep quality and appetite, supporting functional recovery. - Geriatric depression: offers a favorable tolerability profile for elderly patients.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal thoughts or behavior, especially early in treatment - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Mirtazapine, several safety considerations are recommended.

- Assess suicidality: monitor patients for worsening depression or suicidal ideation, especially during initial weeks. - Monitor weight: track changes in appetite and body weight regularly. - Caution in hepatic impairment: adjust use in patients with liver dysfunction. - Avoid abrupt discontinuation: taper dose under medical supervision to reduce withdrawal symptoms. - Use cautiously in elderly: increased risk of sedation and falls. - Store below 25°C: keep in the original container, protect from moisture and light.

Mirtazapine can interact with several drug classes; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crisis. - Strong CYP2D6 inhibitors: may increase mirtazapine plasma levels, raising toxicity risk. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: risk of serotonin syndrome, monitor for symptoms. - Antihistamines: may enhance sedative effects. - Alcohol: can increase CNS depression and impair coordination.